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Editorial
“…decreased cholesterol biosynthesis may lead to decreased hepatic cholesterol 
secretion and consequently to increased bile solubility, which may lower the risk of 
gallstone formation.”
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Is there a link between long-term statin use 
and reduced gallstone risk?
most epidemiological and clinical studies, there 
is conflicting evidence on whether altered LDL 
levels are associated with an altered gallstone 
risk [2]. Several prospective studies reported no 
association between LDL levels and gallstone 
risk, whereas other authors reported either a 
decreased or an increased risk of gallstone dis-
ease in relation to increased LDL levels. Reasons 
for these inconsistencies encompass differences 
in study design, study population, measure-
ment method, bias or residual confounding in 
population-based studies.
“Gallstones are an important cause of 
morbidity in the Western world, leading to 
considerable morbidity and not rarely requiring 
surgical cholecystectomy.”
It is widely recognized that cholesterol hyper-
secretion is crucial in gallstone formation; it 
can be accompanied by high or low secretion 
rates of biliary acids and phospholipid. In addi-
tion, cholesterol supersaturation, accelerated 
nucleation and crystallization and gallbladder 
hypomotility have also been demonstrated to 
contribute to gallstone formation. To date, vari-
ous animal studies and small clinical studies in 
humans have been performed, revealing con-
flicting results as to whether the use of statins 
may decrease bile lithogenicity [3–9]. In theory, 
decreased cholesterol biosynthesis may lead to 
decreased hepatic cholesterol secretion and con-
sequently to increased bile solubility, which may 
lower the risk of gallstone formation. Several, 
but not all, studies demonstrated decreased cho-
lesterol secretion into bile during statin treat-
ment. Furthermore, higher serum levels of HDL 
due to statin use may also be beneficial, since 
decreased HDL serum levels have been linked 
to an increased risk of gallstone disease. On the 
other hand, decreased cholesterol biosynthesis 
We recently published the results of an obser-
vational study in which we analyzed a large 
number of patients who underwent cholecys-
tectomy. Patients who regularly used statins for 
approximately 1 year or more had a substantially 
reduced risk of developing a first-time diagnosis 
of gallstones followed by cholecystectomy com-
pared with patients not using statins [1]. Does 
this finding reflect an important association of 
considerable clinical and public health relevance?
Statins decrease the de  novo biosynthesis 
of cholesterol in the liver in a dose-dependent 
manner by inhibiting the enzyme 3-hydroxy-
3-methyl -glutaryl-coenzyme A reductase – the 
rate limiting step in hepatic cholesterol biosynthe-
sis. Consequently, the synthesis of LDL-receptors 
on the surface of hepatocytes is increased and 
the serum level of LDL-C decreases significantly 
owing to increased hepatic clearance of LDL from 
the blood. Statins also reduce LDL serum levels 
by enhancing removal of VLDL and intermedi-
ate density lipoprotein, and by decreasing hepatic 
VLDL production. Furthermore, statins usually 
decrease plasma triglyceride levels and slightly 
increase HDL-C levels. Usually, maximal effects 
on serum cholesterol levels are achieved within 
a few weeks.
Gallstones are an important cause of morbid-
ity in the Western world, leading to considerable 
morbidity and not rarely requiring surgical cho-
lecystectomy. The majority (~80%) of gallstones 
in the Western world are cholesterol stones; the 
remaining are black and brown pigment stones. 
Known important risk factors for cholesterol 
stones are obesity, female sex, increasing age and 
postmenopausal estrogen-replacement therapy. 
Potential protective factors are regular physical 
activity, high fruit and vegetable diet and cof-
fee consumption. While decreased HDL and 
increased triglyceride levels have been linked 
to an increased risk of gallstone formation in 
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may be associated with diminished formation 
and secretion of hydrophilic bile acids, possibly 
resulting in decreased bile solubility. However, 
the majority of studies reported unchanged bile 
acid synthesis in humans using statins.
“…short-term use of statins was not associated 
with a decreased risk of gallbladder disease 
followed by cholecystectomy.”
The question arises as to whether the risk of 
developing clinically manifest gallstone disease is 
altered by statin use or not. A possible asso ciation 
between statin use and an altered gallstone risk 
has been explored in three large observational 
studies so far [1,10,11]. In 2001, Simon et al. inves-
tigated whether estrogen and progestin supple-
mentation exhibited an increased risk for bile 
tract surgery (mainly cholecystectomy owing 
to gallstone disease) in a randomized, placebo-
controlled trial [11]. Even though use of statins 
was not the major focus of the study, the authors 
noticed that statins were independently asso-
ciated with a reduced risk for bile tract surgery. 
However, the authors did not provide informa-
tion on duration or dosage of statin use. In a large 
cohort encompassing more than 50,000 women 
participating in the Nurses’ Health Study, Tsai 
and coworkers recently analyzed the risk of self-
reported gallstone disease and cholecystectomy 
in association with the use of statins [12]. The 
authors found a moderately decreased adjusted 
relative risk estimate of cholecystectomy for cur-
rent statin users of 0.82 (95% CI: 0.70–0.96) 
compared with nonusers. Again, the investiga-
tors did not report details on exposure time or 
dose, and the study was restricted to women. 
The third study exploring the effect of statin 
use on the risk of gallstone disease followed by 
cholecystectomy was carried out in 2009 by 
our group, the Basel Pharmacoepidemiology 
Unit at the University Hospital of Basel, 
Switzerland [1]. We used the UK-based General 
Practice Research Database (GPRD) to conduct 
a large case–control ana lysis, encompassing 
27,035 cases with gallstone disease followed by 
cholecystectomy and 106,531 controls, matched 
to cases for age, sex, calendar time and general 
practice attended. We found a substantially 
decreased odds ratio for cholecystectomy for 
long-term users (>1–1.5 years) of statins of 0.64 
(95% CI: 0.59–0.70) compared with nonusers. 
Notably, short-term use of statins was not asso-
ciated with a decreased risk of gallbladder dis-
ease followed by cholecystectomy. These results 
were observed across all different statins, and 
there was a tendency towards a lower relative risk 
estimate in patients using higher statin doses. 
However, in contrast to Simon et al., we were not 
able to relate the findings to serum cholesterol 
levels or history of life style habits. However, in 
their study, LDL, HDL and triglyceride serum 
levels were not independently associated with an 
altered risk of biliary tract surgery [12]. Although 
it is recognized that, among other factors, high 
saturated and trans-fat intake, low fiber intake 
and low physical activity are associated with 
an increased risk of gallstones [2,13], all of these 
parameters seemed not to be independent risk 
factors of cholecystectomy in the study by Tsai 
and coworkers [12]. Furthermore, statin users 
tended to have other, more relevant risk factors 
for gallstone disease compared with nonusers, 
such as heavier weight, less physical activity, less 
coffee consumption or use of hormone replace-
ments, which makes the finding related to statins 
even more intriguing [12].
“…statin users tended to have other, more 
relevant risk factors for gallstone disease 
compared with nonusers…”
Taken together, these three studies, all based 
on different study designs and including thou-
sands of patients, strengthen the hypothesis 
that statin use may decrease the risk of gall-
stone disease followed by cholecystectomy in 
clinical practice. However, it must be noted that 
observational data do not allow causality to be 
proven; such studies can only provide evidence 
for a possible association. Therefore, a possible 
causal association needs to be confirmed in a 
randomized prospective trial. However, observa-
tional studies are the only way to explore such a 
hypothesis, since animal models or observations 
in single patients do not justify the conduction 
of a prospective randomized trial. In such a case, 
observational studies using data from estab-
lished databases of high quality can be help-
ful in exploring whether there is any evidence 
that an alleged association of interest may be of 
clinical relevance at all or not. In this case, cur-
rent evidence from observational research does 
provide intriguing evidence that statins may 
indeed reduce the risk of gallstone disease to a 
considerable degree.
Several questions remain to be answered. 
First, despite a substantial amount of available 
data in the literature, no definite mechanism of 
action on how statins may alter bile lithogenicity 
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has been established to date. Second, the time 
dependence of the observed risk reduction was 
assessed in only one study in which the risk 
reduction became evident only after longer-term 
statin use of 1 year or more. By contrast, to our 
knowledge, the previous clinical trials investi-
gating a possible effect of statins on bile litho-
genicity that reported such an effect did so after 
short-term use [3–6]. Third, bringing together all 
available evidence from the literature, high levels 
of LDL per  se (i.e., the most important indi-
cation for statins) are unlikely to be indepen-
dently linked to an increased risk of gallstone 
formation. Therefore, decreased serum levels 
of LDL do not seem to be directly related to a 
potentially decreased risk of gallstone disease 
in statin users. Fourth, to date, no prospective 
randomized trial has been reported assessing the 
risk of gallstone disease followed by cholecys-
tectomy in users of statins compared with non-
users. Given the substantial morbidity and the 
high economic burden of gallstone disease in the 
Western world, the results of such a trial would 
be highly welcome. To date, despite intriguing 
findings in observational studies, there is not 
sufficient evidence to recommend statin therapy 
to lower the risk for gallstone disease. However, 
a possible risk reduction of gallstone disease may 
be looked at as a desired side-effect of statins, if 
the findings can be confirmed.
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